NEW YORK (GenomeWeb News) – DRI Capital will pay Nanogen $10 million for the rights to all future royalties under a licensing agreement between Nanogen and Applied Biosystems.
 
According to a joint announcement from the firms, DRI Capital will receive royalties related to Nanogen’s minor groove binder technology, which was licensed by ABI for use in certain TaqMan products. The MGB technology is used for the design of oligonucleotide probes.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.